NOVAVAX INC (NVAX)       17.32  +0.1 (+0.58%)

17.32  +0.1 (+0.58%)

US6700024010 - Common Stock - After market: 17.31 -0.01 (-0.06%)


Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to NVAX. NVAX was compared to 637 industry peers in the Biotechnology industry. NVAX has a bad profitability rating. Also its financial health evaluation is rather negative. NVAX is quite expensive at the moment. It does show a decent growth rate.




Profitability

Profitability Rating

1

The profitability ratios for NVAX are negative, so there is not much use analyzing them.
NVAX's Return On Assets of -58.30% is worse than the rest of the industry. The industry average Return On Assets is -44.55%.

The Piotroski-F score of NVAX is 3.00. This is a low score and indicates issues in the health and profitability of NVAX.
VS Industry

ROA (-58.3%) VS Industry: 35% outperformed.

-3,944.82
115.38

Valuation

Valuation Rating

0

NVAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year NVAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

5

The Earnings Per Share is expected to grow by 16.03% on average over the next 5 years. This is quite good.
The Revenue has grown by 53.41% in the past year. This is a very strong growth!
NVAX shows a strong growth in Revenue. Measured over the last 5 years, the Revenue has been growing by 136.79% yearly.

Based on estimates for the next 5 years, NVAX will show a decrease in Revenue. The Revenue will decrease by -6.75% on average per year.
The earnings per share for NVAX have decreased strongly by -16.81% in the last year.
The Revenue growth is decreasing: in the next 5 years the growth will be less than in the last years.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -16.81% 96.38% 35.31% 24.2% 16.03%
Revenue136.79% 222.11% 53.41% 61.41% 6.54% 2.15% -6.75%

Health

Health Rating

1

NVAX has a Current Ratio of 1.06. This is a normal value and indicates that NVAX is financially healthy and should not expect problems in meeting its short term obligations.
A Quick Ratio of 1.01 indicates that NVAX should not have too much problems paying its short term obligations.
When comparing the Current Ratio of NVAX to the average industry Current Ratio of 6.11, NVAX is less able to pay its short term obligations than its industry peers. 94% of its industry peers have a better Current Ratio.
Compared to an average industry Quick Ratio of 6.02, NVAX is worse placed to pay its short term obligations than its industry peers. 93% of its industry peers have a better Quick Ratio.

The Debt to Equity ratio of NVAX is negative (-0.06). This means it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
Based on the Altman-Z score of -3.16, we must say that NVAX is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of NVAX to the average industry Altman-Z score of -0.65, NVAX is less financially healthy than its industry peers.
The Piotroski-F score of NVAX is 3.00. This is a low score and indicates issues in the health and profitability of NVAX.
VS Industry

Quick Ratio (1.01) VS Industry: 7% outperformed.

0.02
84.53

Current Ratio (1.06) VS Industry: 6% outperformed.

0.02
85.09

Altman-Z (-3.16) VS Industry: 38% outperformed.

-1,822.17
440.11

Dividend

Dividend Rating

0

NVAX does not give a dividend.

NVAX Daily chart

NOVAVAX INC17.32

NASDAQ:NVAX (12/8/2022, 7:00:02 PM)+0.1 (+0.58%)

After market: 17.31 -0.01 (-0.06%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 02-27 2023-02-27
Ins Owners 0.27% Inst Owners 45.94%
Market Cap 1.36B Analysts 74.29
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 0.74 P/B N/A
EV/EBITDA N/A
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -16.81% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 50.12%
EPS Next Y 96.38% EPS Next 2Y 35.31%
EPS Next 3Y 24.2% EPS Next 5Y 16.03%
Revenue growth 1Y 53.41% Revenue growth 3Y 222.11%
Revenue growth 5Y 136.79% Revenue growth Q2Q 310.74%
Revenue Next Year 61.41% Revenue Next 2Y 6.54%
Revenue Next 3Y 2.15% Revenue Next 5Y -6.75%
Health
Current Ratio 1.06 Quick Ratio 1.01
Altman-Z -3.16 F-Score 3
Debt/Equity -0.06 WACC 9.05%
ROIC/WACC N/A
Profitability
ROA -58.3% ROE N/A
ROICexgc N/A ROIC N/A
PM N/A OM N/A
Asset Turnover 0.81

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA